The role of the C-reactive protein/albumin ratio in determining prognosis of patients diagnosed with small cell lung cancer and the relationship with the diameter and suvmax value of primer mass in PET-CT

Yıl 2020, Cilt: 3 Sayı: 4, 421 - 426, 22.10.2020

Berna Akıncı Özyürek Derya Yenibertiz Aslıhan Gürün Kaya İnci Uslu Biner Sertaç Büyükyaylacı Özden Yurdanur Erdoğan

https://doi.org/10.32322/jhsm.778080

Öz

Introduction: In our study, we aimed to evaluate retrospectively the role of C-reactive protein/ albumin rate (CAR) in determining prognosis of patients diagnosed with SCLC and the relationship with the diameter and SUV max value of primer mass in Positron emission tomography/ computed tomography (PET-CT).
Materials and Methods: A total of 70 patients diagnosed with SCLC between January 2008 and December 2015 in this study. Informations of patients were recorded.
Results: The mean age of the patients was 57.6±7.5. While 59 patients (84.3%) were dead, 11 patients (15.7%) were still alive. The median follow-up time of the patients was 13. 7 (8.1-30.1) month. The mean life span was found to be 21 month in patients with CAR <0.3, and it was found to be 10 month in patients with CAR≥ 0.3 (p=0.007). Median lifespan was 23 month in patients with LDH <187 and it was 10 month in patients with ≥187 (p= 0.048). Median life span was found as 19 month in patients with NLR <3 and it was found to be 10 month in patients with NLR ≥ 3. The result was evaluated as close to statistical significance (p= 0.073).
Conclusion: We detected that male gender, the stage of disease, the increase of SUVmax value of primary mass and increased CAR, NLR and LDH levels were found to be poor prognostic criterias in SCLC patients. We consider that CAR, NLR and LDH levels can be used for forecasting of mortality at the begining of the diagnoses of SCLC

Anahtar Kelimeler

Small cell lung cancer, C-reactive protein, albumin, mortality

Küçük hücreli akciğer kanseri tanısı konulan hastalarda C-reaktif protein/albumin oranının prognoz tayinindeki yeri ile PET-BT’deki primer kitlenin çapı ve suvmax değeri ile ilişkisi

Öz

Giriş-amaç:
Küçük hücreli akciğer kanseri (KHAK) tüm akciğer kanser türlerinin %15’ ini oluşturur. Çalışmamızda KHAK tanısı konulan hastalarda retrospektif olarak ilk tanı anında bakılan C-reaktif protein/ albümin (CAR)’ın prognoz tayinindeki yeri ile primer kitlenin PET-BT’ deki çapı ve SUV max değeri ile ilişkisinin değerlendirilmesini amaçladık.
Materyal-metod:
Çalışmamızda hastanemiz 8. kliniğinde Ocak 2008- Aralık 2015 tarihleri arasında KHAK tanısı konulan 70 hasta dahil edildi. Hastalara ait bilgiler hasta dosyaları ve hastane bilgi sisteminden retrospektif olarak elde edildi. İlk tanı anında bakılan hemogram, biyokimya değerleri, PET-BT’ deki primer kitlenin çapı, SUVmax değerleri, kanser evresi, sağkalım süreleri kayıt edildi. NLR: nötrofil/lenfosit, CAR: C-reaktif protein/albümin oranları hesaplandı.
Bulgular:
Hastaların ortalama yaşı 57,6±7,5 olarak hesaplandı. 59 hasta (%84,3) exitus iken, 11 hasta (%15,7) halen sağ idi. Hastaların median izlem süresi 13,7 (8,1-30,1) ay idi. CAR <0,3 olanlarda ortalama yaşam süresi 21 ay iken, ≥ 0,3 olanlar da 10 ay olarak bulundu (p:0,007). LDH<187 olanlarda median ömür 23 ay, ≥187 olanlarda ise 10 ay olarak bulunmuştur (p: 0 ,048). NLR <3 olanlarda median yaşam süresi 19 ay, ≥ 3 olanlarda 10 ay olarak bulunmuştur. Sonuç istatistiksel olarak anlamlılık sınırına yakın olarak değerlendirilmiştir (p:0,073).
Sonuç:
Erkek cinsiyet, hastalığın evresi ve primer kitlenin SUVmax değerindeki artış, artmış CAR, artmış NLR ve artmış LDH KHAK’lı hastalarda kötü prognoz kriteleri olarak saptadık. CAR, NLR ve LDH düzeylerinin tanı anındaki mortaliteyi öngörmede kullanılabileceklerini düşünmekteyiz.

Anahtar Kelimeler

Küçük hücreli akciğer kanseri, C-reaktif protein, albümin, mortalite

Kaynakça

• Kacan T, Babacan NA, Seker M, et al. Could the neutrophil to lymphocyte ratio be a poor prognostic factor for non small cell lung cancers? Asian Pac J Cancer Prev 2014; 15: 2089-94.
• Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999; 106: 506-12.
• Klonoff-Cohen H, Barrett-Connor EL, Edelstein SL. Albumin levels as a predictor of mortality in the healthy elderly. J Clin Epidemiol 1992; 45: 207-12.
• Koh YW, Lee HW. Prognostic impact of C-reactive protein/albumin ratio on the overall survival of patients with advanced nonsmall cell lung cancers receiving palliative chemotherapy. Medicine (Baltimore) 2017; 96: 6848.
• Mery CM, Pappas AN, Burt BM, et al. Diameter of non-small cell lung cancer correlates with long-term survival: implications for T stage. Chest 2005; 128: 3255-60.
• Brown RS, Leung JY, Kison PV, Zasadny KR, Flint A, Wahl RL. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 1999; 40: 5565.
• Dooms C, van Baardwijk A, Verbeken E, et al. Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic valueof positron emission tomography in early-stage non-small cell lung cancer. J Thorac Oncol 2009; 4: 822-8.
• Li M, Liu N, Hu M, et al. Relationship between primary tumor luorodeoxyglucose uptake and nodal or distant metastases at presentation in T1 stage nonsmall cell lung cancer. Lung Cancer 2009; 63: 383-6.
• Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 9: 1618-26.
• Danner BC, Didilis VN, Wiemeyer S, et al. Long-term survival is linked to serum LDH and partly to tumour LDH-5 in NSCLC. Anticancer Res 2010; 30: 1347-51.
• Zhang X, Guo M, Fan J, et al. Prognostic significance of serum LDH in small cell lung cancer: a systematic review with meta-analysis. Cancer Biomark 2016; 16: 415-23.
• Tas F, Aydiner A, Demir C, Topuz E. Serum lactate dehydrogenase levels at presentation predict outcome of patients with limited-stage small-cell lung cancer. Am J Clin Oncol 2001; 24: 376-8.
• Jin J, Liu D, Zhou Y, Li W. C-reactive protein to albümin ratio as prognostic factors in lung cancer. Int J Clin Exp Med 2017; 10: 16780-7.
• Chatani M, Matayoshi Y, Masaki N, Inoue T. Radiation therapy for brain metastases from lung carcinoma. prospective randomized trial according to the level of lactate dehydrogenase. Strahlenther Onkol 1994; 170: 155-61.
• Chaturvedi AK, Caporaso NE, Ktaki HA: C-reactive protein and risk of lung cancer. JCO. 2010; 28: 2719-26.
• Hong S, Kang YA, Cho BC, Joon D, Yonsei K. elevated serum C-reactive protein as a prognostic marker in small cell lung cancer. Med J 2012; 53: 111-7.
• Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon JE II, Patz EF Jr. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage nonsmall cell lung carcinoma. J Clin Oncol 2008; 26: 1459-64.
• Brown RS, Leung JY, Kison PV, Zasadny KR, Flint A, Wahl RL. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 1999; 40: 556-65.
• Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor ımaging. J Nucl Med 2007; 48: 932-45.
• Kobayashi T, Teruya M, Kishiki T, et al. Inflammation-based prognostic score and number of lymph node metastases are independent prognostic factors in esophageal squamous cell carcinoma. Dig Surg 2010; 27: 232–7.
• Deng M, Ma X, Liang X, Zhu C, Wang M. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer? Oncotarget 2017; 8: 37200-07.
• Akinci Ozyurek B, Sahin Ozdemirel T, Buyukyaylaci Ozden S, Erdogan Y, Kaplan B, Kaplan T. Prognostic value of the neutrophil to lymphocyte ratio (NLR) in lung cancer cases. Asian Pac J Cancer Prev 2017; 18: 1417-21.
• Souhami RL, Law K. Longevity in small cell lung cancer. a report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research. Br J Cancer 1990; 61: 584-9.